Compare · NVO vs RYTM
NVO vs RYTM
Side-by-side comparison of Novo Nordisk A/S (NVO) and Rhythm Pharmaceuticals Inc. (RYTM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RYTM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 30.5x RYTM ($7.31B).
- RYTM has been more active in the news (10 items in the past 4 weeks vs 5 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Novo Nordisk A/S
- Rhythm Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $222.81B
- $7.31B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 5
- 10
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest RYTM
- Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
- Chief Scientific Officer Garfield Alastair converted options into 4,445 shares and covered exercise/tax liability with 2,150 shares, increasing direct ownership by 30% to 10,058 units (SEC Form 4) to cover taxes
- Director Jean Christophe converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)
- Director Mcgirr David W J converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)
- Director Tetrault Lynn A. converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)
- Director Arbuckle Stuart A converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)
- Director Good Jennifer L converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)
- Rhythm Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Tetrault Lynn A. exercised 37,000 shares at a strike of $28.27 and sold $3,711,896 worth of shares (37,000 units at $100.32) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Rhythm Pharmaceuticals Inc.